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BACKGROUND: Only a fraction of molecular cancer markers identified in the scientific literature have found clinical use. Specifically,
few predictors of invasiveness are established in diagnostics. Meta-analysis is a valuable tool for biomarker validation. Here, we
evaluate Osteopontin as a marker for tumor aggressiveness (grade, stage, early progression) and patient survival.
METHODS: Publications through 2008 with the keywords ‘osteopontin AND cancer’ were retrieved. Titles and abstracts were
screened for studies presenting original data on human subjects. This left 228 publications for data extraction. We applied categorical
data analysis for testing the relationship between Osteopontin and a clinical variable.
RESULTS: Osteopontin ranks correlated with lower overall and disease-free/relapse-free survival in all tumors combined, as well as in
lung cancer, breast cancer, prostate cancer, head and neck cancer, and liver cancer. Further, Osteopontin levels correlated with tumor
grade and stage for all tumors combined and for several individual tumor types. Osteopontin levels were significantly associated with
the early progression of eight cancers, independent in one, and inversely correlated in two.
CONCLUSIONS: Osteopontin is significantly associated with survival in several forms of cancer. Osteopontin levels are also markers for
stage, grade, and early tumor progression in multiple cancers, reflecting a common molecular underpinning for distinct clinical
measures. Osteopontin has value as a clinical tumor progression marker.
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In recent years, substantial progress has been made in the
detection and diagnosis of early stage cancers. This is mostly
due to improved imaging technologies and new biomarkers in
histological and hematologic testing. However, there still is a
dearth of molecular indicators that distinguish highly aggressive
tumors from moderately aggressive and non-aggressive ones.
Specifically, few markers that predict invasiveness have been
firmly established. Better molecular prognostics are needed to
accurately assess disease. One candidate marker for the progres-
sion of various malignant tumors has been Osteopontin. In cancer,
this molecule can support cell invasion and anchorage indepen-
dence, thus enhancing tumor progression and metastasis forma-
tion (Weber, 2008). Despite a large literature on Osteopontin as a
cancer marker, it is not in routine diagnostic use. One reason may
be the diversity of source materials and cancer-associated readouts
that have been investigated in correlation to Osteopontin levels.
Therefore, it is important to analyze the comprehensive published
evidence to discern which aspects of cancer pathophysiology are
consistently associated with elevated Osteopontin levels, thus
validating this molecule as a candidate marker.
The scientific literature on biomarkers has grown disproportio-
nately more rapidly than the application of promising markers in
clinical practice. Among the reasons for the delay are high barriers
in the regulatory process and limited available resources for the
recruitment and analysis of sufficiently large patient populations.
Meta-analysis is a suitable approach to enhancing knowledge
about the diagnostic potential of individual biomarkers within
these confines. Yet, conventional regression algorithms have had
limited capability of combining distinct data sets and have
therefore often fallen short of improving confidence. This is a
particular problem for immunohistochemistry, where variable
staining protocols combined with the semi-quantitative nature of
the examination generate substantial study-to-study fluctuations.
Categorical data analysis can limit such heterogeneity. The
evaluation of within-study ranks results in a self-normalization
of variable data sets. When applied to the meta-analysis of
biomarkers, categorical data analysis has a dramatically higher
sensitivity than conventional regression algorithms for detecting
trends in data sets from disparate sources.
METHODS
Data extraction
A PubMed search with the keywords ‘osteopontin AND cancer’
through December 2008 resulted in 800 hits. Titles and abstracts
were screened for studies involving human subjects, yielding
271 papers for initial analysis. 36 articles (including reviews,
commentaries, experiments only on cell lines, no results on cancer,
etc.) did not contain new data on Osteopontin in human cancer. Received 11 May 2010; revised 5 July 2010; accepted 7 July 2010
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sFour articles were not obtained, even after request through
interlibrary loan. Three papers were excluded because they
contained one retraction, one article that pooled diverse primary
tumors without separating them by tumor type, and one paper that
applied scientifically questionable methodology (bidigital O-ring
test). This left 228 publications to be used for data extraction
(Table 1). Of articles not written in English, only the abstracts
(not the full texts) were drawn on for obtaining data. For data
extraction, numbers from the article text were applied directly;
data presented in the format of graphs were measured and
converted to the relevant units. Data from Kaplan-Meier survival
curves were digitized using the software DataThief.
The cancers covered by the original publications include: breast
cancer (34), ovarian cancer (25), liver cancer (21), lung cancer
(20), head and neck cancer (15), colorectal cancer (14), gastric
cancer (14), prostate cancer (13), bone cancer (9), oral cancer (9),
melanoma (9), pancreatic cancer (8), renal cancer (8), esophageal
cancer (7), glioma (7), mesothelioma (7), thyroid cancer (7), endo-
metrial cancer (6), myeloma (6), cervical cancer (4), gestational
trophoblastic tumor (4), leukemia/lymphoma (3), granular cell
tumor (2), non-melanoma skin cancer (2), ampullary cancer (2),
bladder cancer (2), medulloblastoma (2), soft tissue tumors (2),
teratoid tumor (2), adrenocortical cancer (1), neuroblastoma (1),
pilomatricoma (1), renal pelvis cancer (1), von Hippel-Lindau
disease (1). The numbers in parentheses indicate the number of
publications for each type of cancer. Note that several papers
contain data on more than one type of cancer and are counted
here for each. Therefore the sum is larger than the 228 original
publications used for the data extraction.
Data analysis
A significance level of 95% (Po0.05) was applied to all studies.
The correlation between Osteopontin expression levels and the
clinical variables of interest was examined with a categorical
approach (using ranked values). Within a study, the clinical
variables were ranked from low to high and then normalized by the
number of examples in the study. Studies that combined a range of
grades were assigned the mean grade. Also within a study, the
Osteopontin scores were ranked from low to high. In the case of
immunohistochemistry scores that reported graded results on a
0–3
þ scale, a composite score for the study was computed by
weighting each score by the fraction of patients reported for that
score. For studies using an expanded scoring system, the scores
were grouped at low, medium, and high levels and treated in the
same way as the 0–3
þ results. For studies that only reported mean
or median results, the raw values were simply ranked. Ranking
accomplishes a self-normalization within each study (Hong et al,
2006; Hong and Breitling, 2008) and permits the simultaneous
analysis of both the summary results (mean, median only) and
various graded results. In the case of immunohistochemistry, this
reduces the effects of different pathologists scoring the samples. In
other assay types, such as ELISA or quantitative RT-PCR, this
eliminates the need for a normal standard under the assumption
that all samples within a study are compared against the same
standard.
We utilized the Pearson w
2 test (Agresti, 2007) for independence
to assess whether the Osteopontin ranks are independent of the
clinical variable ranks. This test was carried out by constructing
contingency tables using the ranks for each variable, and
populating each cell with the total number of patients reporting
that combination of ranks. Separate tables were constructed for
sets of studies with 2, 3, or more ranks to avoid structural zeros.
The Mantel-Haenszel w
2 test (Agresti, 2007) was used to assess the
hypothesis that the ranking of a particular clinical variable within a
study is linearly related to the Osteopontin level. We then tested
for a non-linear trend by examining the residuals between the
observed values and a linear model of the data.
Receiver operator characteristic (ROC) curves are commonly
used to assess diagnostic performance of a particular measurable
quantity. The most common feature used to quantify this
characteristic is the area under the curve, which can be interpreted
here as the probability that for two randomly chosen samples, the
one with the higher Osteopontin rank will also have a higher rank
for the clinical variable in question (Rice and Harris, 2005). In the
case of the ranked data in this study, that probability can be
calculated for each clinical study. Each pair of patient groups in the
study was examined, and the fraction of those where a group with
higher clinical variable rank also had a higher Osteopontin level
rank is reported here. The statistical significance of this fraction
was tested by carrying out a Monte Carlo simulation to estimate
the distribution of fractions expected for random ranks.
Reporting standards
The data applied to this study were not skewed by publication bias
according to a funnel plot analysis. The present study has been
conducted according to the standards of the PRISMA Statement
(Moher et al, 2009).
RESULTS
Osteopontin in patient survival
We applied categorical meta-analysis to the evaluation of
Osteopontin as a prognostic marker. The distribution of ranks
for published overall and disease-free/relapse-free survival versus
measured Osteopontin levels displayed an aggregation along
the diagonal in bar graphs, indicating a good correspondence
for higher Osteopontin rank to lower mean survival time (Figure
1A and B). To further quantify these results, we determined the
probability that for two patient groups selected at random from a
study, the one that had the higher Osteopontin score would also
have a shorter mean survival time. This resulted in a probability of
90.8%, Po1 10
 5 for overall survival and a probability of 92.9%,
P¼1 10
 4 for disease-free/relapse-free survival, where the
significance was estimated using a permutation test. These results
indicate that Osteopontin rank is a good predictor of survival
outcome rank within a study. The actual probability calculated
from the meta-analysis of the data was significant when compared
to the estimated probability distribution under the null hypo-
thesis that Osteopontin and mean survival time are independent
(Figure 1C and D). When broken down to individual cancers, the
association between Osteopontin levels and overall survival was
significant for lung cancer, breast cancer, prostate cancer, head
and neck cancer, and liver cancer (Table 2). Similar results were
obtained using the meta-analysis function in Oncomine (Supple-
ment 1). For several cancer types, only one published study was
available. Those cases were excluded from the meta-analysis.
In clinical practice, the detection of Osteopontin is particularly
important in two settings. In serum or plasma, Osteopontin may
serve as a prognostic marker associated with a minimally invasive
procedure. After a biopsy, Osteopontin may serve as a prognostic
marker directly linked to the tumor. Therefore, we separately
analyzed the patient survival data for Osteopontin in these
distinct types of specimens. For all cancers combined, the levels
of Osteopontin in plasma, in serum, and in tumors significantly
identified subpopulations with shorter mean survival (Table 3).
In tumors, the highest Osteopontin groups had a mean survival
850 days shorter than the lowest Osteoponin groups. For plasma,
the highest Osteopontin groups had a mean survival 560 days
shorter than the lowest Osteoponin groups. The concordance
between Osteopontin ranks and risk for reduced survival was
confirmed for several individual cancers (Table 3). However, the
sample sizes for several individual cancers were not sufficiently
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(in plasma for gastric, cervical, liver, teratoid, esophageal, and
renal cancers; in serum for breast cancer, head and neck cancer,
and mesothelioma; in tumors for colorectal, ovarian, and prostate
cancers, mesothelioma, and glioma). In tumors, discordance
(i.e. higher Osteopontin groups had longer mean survival times)
was observed for one study each on bone cancer, endometrial
cancer, and melanoma.
Osteopontin in tumor grade, stage and early progression
Osteopontin immunohistochemistry score ranks and tumor grade
and stage ranks were dependent (Po0.001) for all cancers
combined (Figure 2A), as well as for 12 individual cancers for
grade, 13 individual cancers for stage T, 8 individual cancers for
stage N, and 9 individual cancers for stage M (Table 4). Graphical
representation of the group ranks suggested a strong positive
relationship, reflected in a high density of data points along the
Table 1 (Continued)
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Figure 1 Osteopontin in overall survival and in disease-free/relapse-free survival. (A) Overall survival and Osteopontin ranks for all cancers combined.
(B) Disease-free survival and Osteopontin ranks for all cancers combined. (C) Probability Distribution Function for independent Osteopontin and overall
survival ranks. The measured value for Osteopontin data is shown as a vertical line. (D) Probability Density Function for independent Osteopontin and
disease free survival ranks. Measured value for Osteopontin data is shown as a vertical line.
Table 2 Osteopontin and survival in individual cancers
Cancer Concordance P-value Studies
Lung 1.000 0.001 3
Breast 0.917 0.004 8
Prostate 1.000 0.013 3
Head and neck 1.000 0.020 4
Liver 0.875 0.033 8
Cervical 1.000 0.126 3
Esophageal 1.000 0.126 3
Gastric 0.750 0.189 3
Kidney 1.000 0.249 2
Mesothelioma 1.000 0.249 2
Published curves for overall survival were digitised for analysis. P-values in bold are
considered significant. They indicate that Osteopontin over-expression is associated
with elevated risk for death from cancer. For several cancer types, only one published
study was available. Those cases were excluded from the meta-analysis. Shown are
only cancers for which more than one published study was available for evaluation.
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ranked data, we determined the probability that for two patient
groups, the one that had the higher Osteopontin rank would also
have a higher grade or stage rank. In 66.3% of these comparisons,
the group with higher Osteopontin rank was also the group with a
higher tumor grade, which Monte Carlo analysis revealed to be
significant (P¼0.004). Positive comparisons were also seen in
81.3% of cases for tumor stage N (node involvement, P¼0.01),
54.5% of cases for tumor stage T (primary tumor, P¼0.28), and
70% of cases with higher tumor stage M (metastasis, P¼0.18).
For stage T and M, the positive relationship identified in the
comparison of ranks was not statistically significant, possibly due to
insufficient sample size. Advantageously, the categorical analysis can
be applied to heterogeneous data sets. By combining immuno-
histochemistry with the other published tests, we identified a
statistically significant relationship between Osteopontin levels and
all grade and stage measures, including T and M, thus demonstrat-
ing the benefit of incorporating all of the available data within one
analysis (Figure 2C). The categorical analysis had higher sensitivity
than a conventional meta-analysis approach (Supplement 2).
In the early stages of transformation, tumor progression can be
described as the transition from normal tissue to precancerous
lesions (dysplasia, metaplasia), preinvasive cancer, and cancer.
According to categorical meta-analysis, Osteopontin expression
levels were significantly associated with the progression of eight
cancers, independent in one, and inversely correlated in two (skin
cancer and gestational trophoblastic tumor) (Table 5). Of note, while
Osteopontin appears to be a cancer biomarker for 31 individual
malignancies its levels were significantly reduced below normal in
non-melanoma skin cancer and gestational trophoblastic tumor. This
suggests a unique role for Osteopontin in these two malignancies.
DISCUSSION
High levels of Osteopontin in several cancers are indicative of a
poor prognosis. Overall and disease-free survival are inversely
related to Osteopontin levels in several cancers. There is strong
correspondence between high Osteopontin and lower mean
survival time in tumor (82%) and plasma (100%) measurements,
with large mean differences in survival times, indicating a useful
role for Osteopontin in patient stratification, Patient survival is
largely determined by tumor aggressiveness. Hence, it is not
unexpected that Osteopontin, a prognostic measure for survival, is
also a marker for grade, stage, and early progression. It is likely
Table 3 Osteopontin and survival in distinct clinical specimens
Number of studies Concordance P-value
Specimen
(A) All tumors combined
Tumor 31 0.825 o0.0001
Plasma 14 1 o0.0001
Serum 3 1 0.04
Cancer type
(B) Plasma, individual cancers
Lung 1 1 0.00
Prostate 2 1 0.08
Breast 2 1 0.08
Head and neck 3 1 0.13
Cancer type
(C) Tumor, individual cancers
Liver 7 0.857 0.06
Breast 5 0.800 0.19
Esophageal 2 1 0.24
Head and neck 2 1 0.25
Lung 2 1 0.25
Cervical 2 1 0.25
Gastric 2 0.714 0.28
The concordance and probability of error were calculated for the null-hypothesis that
Osteopontin levels are not correlated with high risk for short survival. (A) All tumors
combined in distinct types of clinical samples. (B) Plasma Osteopontin in individual
cancers (for serum Osteopontin see main text). (C) Tumor Osteopontin in individual
cancers. Bold values indicate Po0.1
Clinical variable Pearson 2 Studies Patients
Tumor grade
A
Tumor stage -T
Tumor stage -N
Tumor stage -M
P < 0.001 31 3370
P < 0.001 20 1891
P < 0.001 16 2069
P < 0.001 10 961
B
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Clinical variable Fraction Signiﬁcance
Tumor grade
C
Tumor stage - T
Tumor stage - N
Tumor stage - M
0.67 P = 0.002
0.7 P < 0.001
0.84 P < 0.001
0.82 P = 0.006
Figure 2 By categorical meta-analysis, Osteopontin levels correlate with
stage and grade of cancers. (A) The Pearson w
2 test of ranked Osteopontin
immunohistochemistry scores with tumor grade and stage shows a
significant dependence between Osteopontin rank and clinical variable.
(B) The bar graphs of Osteopontin rank versus rank of grade or stage
display an aggregation of data along the diagonal, indicating a positive
relationship between Osteopontin levels and clinical variables. The
associations are statistically significant for grade and node positivity, but
not for stage T and M. (C) Expanded analysis of grade and stage ranks to all
published measures. In five studies with duplicate data sets only the
immunohistochemistry results were used. We computed a measure
analogous to that represented by the area under a ROC curve (see
Methods). For all grade and stage measures, Osteopontin is a significant
positive indicator.
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warrant more forceful treatment regimens than are suitable for
patients with low levels of Osteopontin.
Although tumor grade, tumor stage, and early tumor progres-
sion are distinct measures for the clinical presentation of a
cancer they are not mutually unrelated. A dedifferentiated, high
grade tumor is more aggressive, and consequently more likely
to disseminate and become high stage than a low grade tumor.
The molecular mechanisms driving progression, grade, and stage
are overlapping. Osteopontin is associated with all of them. In
patient care, the diagnosis and assessment of cancer is typically
made on the basis of clinical and histo-morphologic criteria.
However, molecular markers are more quantifiable and may be
more reflective of underlying disease mechanisms. The incomplete
convergence between clinical and molecular descriptors may
require a reevaluation of how we assess cancer (Weber, 2010).
Table 4 Categorical meta-analysis of tumor grade and stage
Cancer type Studies Patients Pearson P-value Linear P-value Correlation coefficient Non-linear P-value
(A) Tumor grade
All 42 4408 o0.001 o0.001 0.27 o0.001
Breast 6 1061 o0.001 o0.001 0.28 o0.001
Endometrial 3 236 o0.001 0.004  0.19 o0.001
Esophageal 2 161 o0.001 0.001  0.26 o0.001
Gastric 3 428 o0.001 o0.001  0.65 o0.001
Glioma 5 180 o0.001 o0.001 0.89 o0.001
Head & neck 2 92 o0.001 o0.001 0.59 o0.001
Liver 6 870 o0.001 o0.001 0.72 o0.001
Lung 4 610 o0.001 o0.001  0.24 o0.001
Oral 3 103 o0.001 0.170 0.14 o0.001
Ovarian 5 379 o0.001 o0.001 0.68 o0.001
Prostate 2 117 o0.001 o0.001 0.45 o0.001
Renal 1 171 o0.001 o0.001 1 1
(B) Tumor stage (T)
All 56 4480 o0.001 o0.001 0.70 o0.001
Breast 3 236 o0.001 0.003 0.20 o0.001
Cervical 2 170 0.416 0.417  0.06 N/A
Colorectal 6 420 o0.001 o0.001 0.84 o0.001
Endometrial 4 122 o0.001 0.052  0.18 o0.001
Esophageal 6 284 o0.001 o0.001 0.67 o0.001
Gastric 8 772 o0.001 o0.001 0.85 o0.001
Head & neck 5 569 o0.001 o0.001 1.00 N/A
Liver 4 497 o0.001 o0.001 0.89 o0.001
Lung 5 692 o0.001 o0.001 0.96 o0.001
Myeloma 1 30 o0.001 o0.001 1.00 N/A
Oral 1 26 o0.001 o0.001  1.00 1
Ovarian 8 444 o0.001 o0.001 0.22 o0.001
Prostate 1 47 o0.001 o0.001  1.00 1
Renal 1 171 o0.001 o0.001 1.00 N/A
(C) Tumor stage (N)
All 27 3159 o0.001 o0.001 0.81 o0.001
Breast 7 909 o0.001 o0.001 0.59 N/A
Esophageal 3 336 o0.001 o0.001 1.00 N/A
Gastric 7 1013 o0.001 o0.001 1.00 N/A
Head & neck 4 469 o0.001 o0.001 1.00 N/A
Liver 2 145 0.055 0.056  0.16 N/A
Lung 1 130 o0.001 o0.001 0.43 o0.001
Melanoma 1 68 o0.001 o0.001 1.00 N/A
Oral 1 46 o0.001 o0.001 1.00 N/A
Renal 1 43 o0.001 o0.001 1.00 N/A
(D) Tumor stage (M)
All 28 1900 o0.001 o0.001 0.72 N/A
Bladder 1 23 o0.001 o0.001 1.00 N/A
Breast 3 102 o0.001 o0.001 0.34 N/A
Colorectal 1 10 0.002 0.003 1.00 N/A
Gastric 4 612 o0.001 o0.001 1.00 N/A
Head & neck 3 113 o0.001 o0.001 1.00 N/A
Liver 5 187 o0.001 o0.001  0.40 N/A
Lung 6 644 o0.001 o0.001 0.75 N/A
Melanoma 2 43 o0.001 o0.001 1.00 N/A
Oral 1 26 o0.001 o0.001 1.00 N/A
Prostate 1 10 0.002 0.003 1.00 N/A
Thyroid 1 130 o0.001 o0.001 1.00 N/A
Published Osteopontin levels in relation to tumor grade or tumor stage were analyzed. As a test for independence of the ranked data we used the Pearson w
2-test. To assess
linear and non-linear trends of the ranked data we applied the Mantel–Haenszel w
2-test. N/A indicates that there were only two outcomes, and a non-linear fit is not measurable.
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sion rank and stage or grade rank was 67–84% over all types
of cancer. This is comparable to the accuracy commonly
estimated for existing tumor markers, including CEA, CA 15-3,
CA 19-9 and PSA (Ebert et al, 1996; Koopmann et al, 2006;
Ulmert et al, 2009). When applied to select cancers, the accuracy
of Osteopontin increases. Future research needs to assess whether
the combination of Osteopontin with other markers can
further improve its diagnostic value (Reinholz et al, 2002; O’Neill
et al, 2005; Alonso et al, 2007; Ribeiro-Silva and Oliveira da Costa,
2008).
Meta-analysis has been a valuable tool in biomarker validation.
One of its major limitations is the detection of true signals over the
noise of heterogeneous input data. Categorical data analysis has
a self-normalizing effect on study-to-study variations and may
therefore be superior to conventional meta-regression algorithms.
For the evaluation of Osteopontin as a biomarker for cancer, we
have found conventional and categorical meta-analysis to be in
agreement. This was not the case for the correlation of Osteopontin
levels with tumor grade and stage (Figure 2 and Supplementary
Figure S1). Here, the improved sensitivity of the categorical
analysis is required to detect the existing trends in the published
data sets.
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Table 5 Categorical meta-analysis of tumor progression
Cancer Type Studies Patients Pearson P-value Linear P-value Correlation coefficient Non-linear P-value
All 34 2425 o0.001 o0.001 0.68 o0.001
Breast 4 172 o0.001 o0.001 0.75 o0.001
Cervical 1 398 o0.001 o0.001 1.00 1
Esophageal 1 46 o0.001 o0.001 0.77 o0.001
Gestational Trophoblastic tumor 4 86 o0.001 o0.001  1.00 N/A
Head and neck 1 82 o0.001 o0.001 1.00 1
Liver 7 731 o0.001 o0.001 0.68 N/A
Mesothelioma 3 148 o0.001 o0.001 1.00 1
Myeloma 3 208 o0.001 o0.001 1.00 1
Non-mel. 1 36 o0.001 o0.001  1.00 N/A
Oral 2 230 o0.001 o0.001 0.86 o0.001
Ovarian 5 213 o0.001 o0.001  0.80 o0.001
Prostate 2 75 o0.001 o0.001 1 N/A
In the early stages of transformation, tumor progression can be described as the transition from normal tissue to precancerous lesions (dysplasia, metaplasia), preinvasive cancer,
and cancer. The ranked levels of Osteopontin expression are significantly associated with the progression of liver cancer, myeloma, head and neck cancer, cervical cancer,
prostate cancer, oral cancer, breast cancer, and mesothelioma. Unexpectedly, the meta-analysis reveals an inverse correlation to the progression of skin cancer and gestational
trophoblastic tumor. Non-mel.¼non-melanoma skin cancer.
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